NIFK antisense RNA 1 (NIFK-AS1)

NIFK antisense RNA 1 (NIFK-AS1) is a long non-coding RNA that functions as a natural antisense transcript, meaning it is transcribed from the strand opposite to its associated sense gene. As an lncRNA, it does not code for a protein but instead modulates biological processes by regulating gene expression, often through interactions with messenger RNAs, microRNAs, or chromatin-modifying complexes[1][2]. While NIFK-AS1 has been observed to promote the development and progression of endometrial cancer, its role in other cancer types and diseases continues to emerge. In the context of endometrial cancer, NIFK-AS1 acts as an oncogenic lncRNA and is associated with increased tumor growth and invasion[2]. Like other natural antisense transcripts, NIFK-AS1 can influence gene expression via transcriptional interference, epigenetic regulation, or alterations in RNA splicing[1]. NIFK-AS1 is not a conventional druggable target (e.g., receptor, enzyme), but a non-coding RNA with regulatory capacity; therefore, it is not currently targeted by approved therapeutics[1][2]. No direct interactions with approved drugs or candidate therapies have been documented to date. Research continues into the broader roles of antisense lncRNAs such as NIFK-AS1 in cancer and precision medicine.

Other names

NIFK-AS1

Not applicable; NIFK-AS1 itself is a regulatory RNA and not currently the direct target of pharmacological agents—rather, it acts by modulating the expression of genes or interacting with microRNAs